This report is dated as of 9/9/00. This report is for informational purposes only and is not a recommendation to buy or sell this stock. Please see our disclaimer.
Geron's home page is at http://www.Geron.com . Get a quote at yahoo at http://quote.yahoo.com/q?s=gen&d=v1 Geron Corporation is a biopharmaceutical company that is focused on discovering, developing and commercializing therapeutic and diagnostic products for applications in oncology, drug discovery and regenerative medicine. Geron's product development programs are based upon three patented, independent and synergistic technologies: telomerase, human pluripotent stem cells, and nuclear transfer. Since inception, substantially all of the Company's revenues have been generated from license and research agreements with collaborators. In addition, the Company receives license payments and royalties from license and marketing agreement with various diagnostic and research tool collaborators. This stock may cure aging one day or it may go out of business. If you invest in this stock please use only an amount you are willing to lose as it is very risky. We also recommend cutting your loses at 8% of your original investment. The stock is currently in an MACD uptrend, which is good. Stock is up 12.9% in the last 3 months, down 49% in the last 6 months and up 175% in the last 12 months. Its 52-week high is $75.87. According to their 10Q there are no legal proceedings against Geron. Morningstar.com rates Geron as an F for Growth, D- for profitability, D for financial health, and an NA for valuation. Barchart.com rates 40% short term buy, 75% Medium term buy and long-term 67% buy. To do a complete analysis go to http://StockG.com/q.htm?em
One risk is whether a Gore presidency will negatively affect the valuations of the biotech industry.
Some links: